AIMS: Hyperkalaemia is a common complication of type 2 diabetes mellitus (T2DM) and limits the optimal use of agents that block the renin-angiotensin-aldosterone system, particularly in patients with chronic kidney disease (CKD). In patients with CKD, sodium‒glucose cotransporter 2 (SGLT2) inhibitors provide cardiorenal protection, but whether they affect the risk of hyperkalaemia remains uncertain.METHODS AND RESULTS: The CREDENCE trial randomized 4401 participants with T2DM and CKD to the SGLT2 inhibitor canagliflozin or matching placebo. In this post hoc analysis using an intention-to-treat approach, we assessed the effect of canagliflozin on a composite outcome of time to either investigator-reported hyperkalaemia or the initiation of p...
Background: Chronic kidney disease (CKD) risk is elevated in patients with type 2 diabetes mellitus ...
Introduction: Mineralocorticoid receptor antagonists (MRAs) and sodium-glucose cotransporter-2 (SGLT...
RATIONALE AND OBJECTIVE: Canagliflozin reduced the risk of kidney failure and related outcomes in pa...
AIMS: Hyperkalaemia is a common complication of type 2 diabetes mellitus (T2DM) and limits the optim...
Aims: Hyperkalaemia is a common complication of type 2 diabetes mellitus (T2DM) and limits the optim...
AIMS: Hyperkalaemia is a common complication of type 2 diabetes mellitus (T2DM) and limits the optim...
Background: The sodium-glucose cotransporter 2 inhibitor canagliflozin has been shown to reduce the ...
Background: Hyperkalemia increases risk of cardiac arrhythmias and death and limits the use of renin...
RATIONALE AND OBJECTIVE: Canagliflozin reduced the risk of kidney failure and related outcomes in pa...
Background: Hyperkalemia increases risk of cardiac arrhythmias and death and limits the use of renin...
Background: People with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) experience ...
Background: Chronic kidney disease (CKD) risk is elevated in patients with type 2 diabetes mellitus ...
Introduction: Mineralocorticoid receptor antagonists (MRAs) and sodium-glucose cotransporter-2 (SGLT...
RATIONALE AND OBJECTIVE: Canagliflozin reduced the risk of kidney failure and related outcomes in pa...
AIMS: Hyperkalaemia is a common complication of type 2 diabetes mellitus (T2DM) and limits the optim...
Aims: Hyperkalaemia is a common complication of type 2 diabetes mellitus (T2DM) and limits the optim...
AIMS: Hyperkalaemia is a common complication of type 2 diabetes mellitus (T2DM) and limits the optim...
Background: The sodium-glucose cotransporter 2 inhibitor canagliflozin has been shown to reduce the ...
Background: Hyperkalemia increases risk of cardiac arrhythmias and death and limits the use of renin...
RATIONALE AND OBJECTIVE: Canagliflozin reduced the risk of kidney failure and related outcomes in pa...
Background: Hyperkalemia increases risk of cardiac arrhythmias and death and limits the use of renin...
Background: People with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) experience ...
Background: Chronic kidney disease (CKD) risk is elevated in patients with type 2 diabetes mellitus ...
Introduction: Mineralocorticoid receptor antagonists (MRAs) and sodium-glucose cotransporter-2 (SGLT...
RATIONALE AND OBJECTIVE: Canagliflozin reduced the risk of kidney failure and related outcomes in pa...